Clinical Trial for Dogs with Atrial Fibrillation and Structural Heart Disease

Breed(s): -All Dogs
Study Type: Clinical Study
Study Location: Colorado State University, College of Veterinary Medicine & Biomedical Sciences

CHF-funded researcher Dr. Janice Bright and her team at Colorado State University are seeking canine patients (all breeds and mixed breeds) with atrial fibrillation and structural heart disease of any type or severity to enroll in a clinical trial.

Atrial fibrillation (AF) is a common heart rhythm abnormality (arrhythmia) in dogs. This arrhythmia affects all dog breeds and frequently coexists with heart failure (HF) causing worsening of HF and high mortality. AF may be managed by administering drugs to slow heart rate or by restoring normal rhythm (cardioversion). Slowing rate often does not provide adequate relief and may accelerate progression of HF. Cardioversion safely restores normal rhythm and mitigates HF in >80% of affected dogs. However, owners often decline cardioversion because of possible relapse of AF despite routine use of the antiarrhythmic agent, amiodarone. Ranolazine is a pharmaceutical agent marketed for people with coronary heart disease; however, this drug has significant anti-AF effects. Combined administration of ranolazine and amiodarone provides greater suppression of AF in humans and research dogs than either drug alone. Ranolazine also improves contraction of heart muscle in dogs with experimental HF. Ranolazine lacks significant adverse effects and can be safely administered to dogs with HF.

Dr. Bright and her team will determine whether ranolazine, given with amiodarone, prolongs normal rhythm after cardioversion compared to amiodarone alone and whether ranolazine also improves heart function. Dogs with naturally occurring AF and heart disease will be studied. After cardioversion dogs will receive either amiodarone/placebo or amiodarone/ranolazine in a randomized, blinded manner. Duration of normal rhythm and measurements of heart function over time will be compared between groups. Results will validate combined ranolazine/amiodarone administration as an improved new treatment for AF in dogs with HF. No invasive or experimental diagnostics are required.

More Information


Contact Information:
Name: Dr. Jan Bright
Phone: 970-297-5000

Help Future Generations of Dogs

Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.

Learn How to Help

Make an Investment Today:

  • $50
  • $100
  • $250
  • $1000
  • Give Now
Connect With Us:
Get Canine Health News:
Please leave this field empty

© 2016 AKC Canine Health Foundation | Privacy Policy | Site Map

Site by Blackbaud, Inc.

Powered by Blackbaud
nonprofit software